KRAS G12D

BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...

REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...